{"id":"https://openalex.org/W4412949396","doi":"https://doi.org/10.1016/s2352-3026(25)00195-4","title":"Adverse event grading: the case of Duffy null-associated neutrophil counts","display_name":"Adverse event grading: the case of Duffy null-associated neutrophil counts","publication_year":2025,"publication_date":"2025-08-01","ids":{"openalex":"https://openalex.org/W4412949396","doi":"https://doi.org/10.1016/s2352-3026(25)00195-4","pmid":"https://pubmed.ncbi.nlm.nih.gov/40769681"},"language":"en","primary_location":{"id":"doi:10.1016/s2352-3026(25)00195-4","doi":"https://doi.org/10.1016/s2352-3026(25)00195-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2352-3026(25)00195-4","pdf_url":null,"source":{"id":"https://openalex.org/S2531671668","display_name":"The Lancet Haematology","issn_l":"2352-3026","issn":["2352-3026","2451-9960"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Haematology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047357200","display_name":"Stephen P. Hibbs","orcid":"https://orcid.org/0000-0002-3663-2742","observed_orcids":["https://orcid.org/0000-0002-3663-2742"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Stephen P Hibbs","raw_affiliation_strings":["Wolfson Institute of Population Medicine, Queen Mary University of London, London E1 2AB, UK. Electronic address: s.p.hibbs@qmul.ac.uk"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wolfson Institute of Population Medicine, Queen Mary University of London, London E1 2AB, UK. Electronic address: s.p.hibbs@qmul.ac.uk","institution_ids":["https://openalex.org/I166337079"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015976295","display_name":"Lauren E. Merz","orcid":"https://orcid.org/0000-0002-6618-803X","observed_orcids":["https://orcid.org/0000-0002-6618-803X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I48633490","display_name":"Mass General Brigham","ror":"https://ror.org/04py2rh25","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lauren E Merz","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of Hematology/Oncology, Department of Medicine, Mass General Brigham, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of Hematology/Oncology, Department of Medicine, Mass General Brigham, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069251789","display_name":"Andrew Hantel","orcid":"https://orcid.org/0000-0001-9612-3643","observed_orcids":["https://orcid.org/0000-0001-9612-3643"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Hantel","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Bioethics, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Bioethics, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5047357200"],"corresponding_institution_ids":["https://openalex.org/I166337079"],"apc_list":{"value":7280,"currency":"USD","value_usd":7280},"apc_paid":null,"fwci":1.0367,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.72282556,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":95},"biblio":{"volume":"12","issue":"8","first_page":"e567","last_page":"e567"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.6859999895095825,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.6859999895095825,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.1607999950647354,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10582","display_name":"Ethics in Clinical Research","score":0.03539999946951866,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adverse-event-grading","display_name":"adverse event grading","score":0.9129999876022339},{"id":"https://openalex.org/keywords/adverse-event-reporting","display_name":"adverse event reporting","score":0.7720000147819519},{"id":"https://openalex.org/keywords/population-variation","display_name":"population variation","score":0.421999990940094},{"id":"https://openalex.org/keywords/health-equity","display_name":"health equity","score":0.8579999804496765},{"id":"https://openalex.org/keywords/adverse-event-definitions","display_name":"adverse event definitions","score":0.4339999854564667}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9016445279121399},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5002772808074951},{"id":"https://openalex.org/C74133956","wikidata":"https://www.wikidata.org/wiki/Q4669824","display_name":"Absolute neutrophil count","level":4,"score":0.495307594537735},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39028745889663696},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.26922184228897095},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.11714059114456177}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/s2352-3026(25)00195-4","doi":"https://doi.org/10.1016/s2352-3026(25)00195-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2352-3026(25)00195-4","pdf_url":null,"source":{"id":"https://openalex.org/S2531671668","display_name":"The Lancet Haematology","issn_l":"2352-3026","issn":["2352-3026","2451-9960"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Haematology","raw_type":"journal-article"},{"id":"pmid:40769681","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40769681","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet. Haematology","raw_type":"Letter"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320311904","display_name":"Wellcome Trust","ror":"https://ror.org/029chgv08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W3087631144","https://openalex.org/W4381309111","https://openalex.org/W4402455502","https://openalex.org/W4404643652","https://openalex.org/W4410800025"],"related_works":["https://openalex.org/W7117487760","https://openalex.org/W2139071977","https://openalex.org/W4381309111","https://openalex.org/W2770769002","https://openalex.org/W4412512392","https://openalex.org/W4414867254","https://openalex.org/W4415027503","https://openalex.org/W4410800072","https://openalex.org/W4415614328","https://openalex.org/W2133415831"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-10-10T00:00:00"}